Shots:
- Neurimmune has entered into an exclusive global collaboration & licensing deal with Alexion to develop NI009, a preclinical human mAb for the treatment of AL amyloidosis
- Alexion will obtain an exclusive global license to Neurimmune’s AL amyloidosis–targeting Abs, incl. NI009, with Neurimmune handling preclinical activities, early manufacturing & the FIH study, while Alexion will handle subsequent clinical development, manufacturing & commercialization
- As per the deal, Neurimmune will receive an undisclosed upfront & ~$780M in development, regulatory & commercial milestones, as well as tiered royalties on net sales of products resulting from the deal
Ref: Neurimmune | Image: Neurimmune & Alexion|Press Release
Related News: Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
